COVID–19 NEWS   Vietnam's COVID-19 cases nears 15,000 on Sunday | COVID: 3,856 new cases, 99.1 pct in categories one and two - Health Dg | New Zealand to escalate to red light settings due to Omicron community transmission | COVID: Sabah records fifth educational institution-linked cluster | Report : Singapore reports first Omicron-related death | 
EXCLUSIVE PRESS

Adagene Announces First Patients With Advanced Non-Small Cell Lung Cancer Dosed In Phase 1b/2 Clinical Trial Of ADG106 In Combination With Nivolumab In Singapore

13/01/2022 06:26 PM

Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium

SAN DIEGO and SUZHOU, China, Jan 13 (Bernama) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that the first patients have been dosed in a phase 1b/2 clinical trial of the anti-CD137 agonist antibody, ADG106, in combination with the anti-PD-1 antibody, Nivolumab for patients with advanced non-small cell lung cancer (NSCLC) who have progressed on prior therapies.


Bernama is the trusted source of reliable real-time comprehensive and accurate news for both the public and media practitioners. Our news is published at www.bernama.com ; BERNAMA TV on: Astro Channel 502, unifi TV Channel 631, MYTV Channel 121 IFLIX; and Bernama Radio broadcasting locally on FM93.9 in Klang Valley, Johor (FM107.5), Kota Kinabalu (FM107.9) and Kuching (FM100.9).

Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial

For full news, click here

© 2022 BERNAMA   • Disclaimer   • Privacy Policy   • Security Policy